中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

18 records (took 0.022 seconds)

    The use of inhibitors of bruton’s tyrosine kinase (btk)
    5.
    发明专利
    The use of inhibitors of bruton’s tyrosine kinase (btk) 未知

    公开(公告)号：NZ604040A

    公开(公告)日：2015-02-27

    申请号：NZ60404011

    申请日：2011-06-03

    Applicant: PHARMACYCLICS INC

    Inventor： HEDRICK ERIC ,  MODY TARAK D ,  BUGGY JOSEPH J ,  LOURY DAVID J ,  ELIAS LAURENCE ,  FYFE GWEN

    IPC: A61K31/4162 ,  A61K31/519 ,  A61K31/505 ,  A61P35/00 ,  A61P35/02 ,  C07D487/04

    Abstract: Disclosed is the use of (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one (ibrutinib / PCI-32765) (an inhibitor of Bruton’s tyrosine kinase (Btk)) for the manufacture of a medicament for the treatment of mantle cell lymphoma in an individual who has already received at least one prior therapy for mantle cell lymphoma, wherein the medicament is suitable for oral administration once per day of a dose of about 420 mg to about 840 mg. Also disclosed it the use of ibrutinib for the manufacture of a medicament for the treatment of relapsed or refractory chronic lymphocytic leukemia or relapsed or refractory small lymphocytic leukemia in an individual, wherein the medicament is suitable for oral administration once per day of a dose of about 420 mg to about 840 mg, and wherein the medicament optionally further comprises an additional cancer treatment regimen comprising bendamustine, bortezomib, CAL-101, chlorambucil, cyclophosphamide, dexamethasone, docetaxel, doxorubicin, endostatin, everolimus, etoposide, fludarabine, fostamatinib, hydroxydaunorubicin, ibritumomab, ifosphamide, lenalidomide, mesalazine, ofatumumab, paclitaxel, pentostatin, prednisone, rituximab, temsirolimus, thalidomide, tositumomab, vincristine, or a combination thereof, such as rituximab, fludarabine and cyclophosphamide, or rituximab, cyclophosphamide, hydroxdaunorubicin, vincristine and prednisone.

Patent Agency Ranking